Enzyme Or Coenzyme Containing Patents (Class 424/94.1)
  • Patent number: 11364205
    Abstract: The present invention is directed to a pharmaceutical composition or dosage form having a stable, low (diluted) digestive enzyme content comprising at least one digestive enzyme and at least one carrier, or a dosage form thereof. The invention is also directed to a process of preparation of the composition or the dosage form. In addition the invention is directed to the treatment and prevention of disorders or conditions associated with a digestive enzyme deficiency in a patient in need thereof, comprising administering to said patient a pharmaceutically acceptable amount of the composition having a stable low digestive enzyme content or dosage form thereof.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: June 21, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Giovanni Ortenzi, Giuseppe De Franza, Danilo Clementi, Christian Stollberg, Luigi Boltri
  • Patent number: 11364282
    Abstract: The present invention relates i.a. to compositions which are suitable for treatment of infertility or subfertility, in particular infertility or subfertility caused by polycystic ovary syndrome (PCOS)or anovulation, or which are suitable for treatment of PCOS or anovulation itself.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: June 21, 2022
    Assignee: LO.LI. PHARMA S.R.L.
    Inventor: Vittorio Unfer
  • Patent number: 11337957
    Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: May 24, 2022
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher Rinsch, William Blanco-Bose
  • Patent number: 11326209
    Abstract: The present invention relates to a cell based genomic Recorded Accumulative Memory (geRAM) system (also referred to herein as Genomically Encoded Memory (GEM)) for recoding data (i.e., changes in nucleic acid sequences in cellular DNA in response to physical and/or chemical signal(s)) from the cellular environment.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: May 10, 2022
    Assignees: Massachusetts Institute of Technology, Whitehead Institute of Biomedical Research
    Inventors: Joseph M. Jacobson, Noah Jakimo, Naama Kanarek, David Sabatini
  • Patent number: 11324685
    Abstract: The present invention relates to a process for treating hair wherein the hair is semi permanently shaped and subsequently reshaped with the application of an aqueous composition comprising catechin and/or resorcinol and their derivatives.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 10, 2022
    Assignee: KAO GERMANY GMBH
    Inventors: Bernd Nöcker, Steven Breakspear, Niu Jian
  • Patent number: 11319423
    Abstract: A foamable, insulating-layer-forming multi-component composition contains alkoxysilane-functional polymer, insulating-layer-forming fire-protection additive, blowing-agent mixture, cross-linking agent, and a flame-protection agent that is miscible in water or another compound that is miscible in water. The individual ingredients of the blowing-agent mixture are separated from one another to ensure inhibition of reaction prior to use of the composition, and the cross-linking agent is separated from the alkoxysilane-functional polymer to ensure inhibition of reaction prior to use of the composition. The foamable, insulating-layer-forming multi-component composition can be used as a foam-in-place foam or for production of molded blocks.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: May 3, 2022
    Assignee: Hilti Aktiengesellschaft
    Inventors: Jekaterina Miller, Mario Paetow
  • Patent number: 11311565
    Abstract: The invention disclosed herein relates to a novel synergistic nutritional composition for promoting axonal regeneration. Particularly, the present invention provides potent nutritional composition comprising synergistic exogenous blend of agmatine (decarboxylated L-arginine) and inosine monophosphate (IMP) and salts thereof, which are present in a weight ratio of 1:0.05 to 1:2 along with pharmaceutically acceptable excipients. The instant synergistic nutritional composition is useful for treating diseases or disorders related to traumatic injury in the central nervous system such as brain or spinal cord injury, optic nerve lesions.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: April 26, 2022
    Assignee: CELAGENEX RESEARCH (INDIA) PVT. LTD.
    Inventors: Rajaram Samant, Rajendra Prasad Tongra
  • Patent number: 11302434
    Abstract: A computer system provides nutrition-based management of health conditions using machine learning. Health information of a user is evaluated to determine a health condition. Medication information for the user is analyzed and the medication information is mapped to the health condition. One or more natural treatments for the user are determined from information sources based on the mapped health condition and medication information, wherein the one or more natural treatments include one or more from a group of nutrition and mind/body treatments, and wherein the information sources include information from crowdsourcing. The one or more natural treatments and medication information for the health condition are indicated. Embodiments of the present invention further include a method and program product for providing nutrition-based management of health conditions using machine learning in substantially the same manner described above.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: April 12, 2022
    Assignee: International Business Machines Corporation
    Inventors: Diane Whalen, Fang Lu
  • Patent number: 11278856
    Abstract: A lutein microcapsule formulation and preparation method thereof, the formulation comprising the following ingredients: lutein crystals, a water-soluble emulsifier, an oil-soluble antioxidant, a wall material, a filler, a water-soluble antioxidant, and purified water. The preparation method comprises: dissolving the lutein crystals and the oil-soluble antioxidant in the water-soluble emulsifier to obtain an oil phase; adding the wall material, the water-soluble antioxidant, and the filler to the purified water to obtain a water phase; adding the oil phase to the water phase, grinding to obtain a particle size of the liquid emulsion of less than 100 nm, and granulating.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: March 22, 2022
    Assignee: CHENGUANG BIOTECH GROUP CO., LTD
    Inventors: Qingguo Lu, Jianzhong Xu, Yunhe Lian
  • Patent number: 11268091
    Abstract: The invention is directed to methods for synthesizing oligonucleotides directly on biomolecules or cells living or fixed. In some embodiments, template-free enzymatic synthesis is implemented under biological conditions with successive cycles of (i) enzymatic addition of a 3?-O-blocked nucleoside triphosphate and (ii) enzymatic deblocking of the incorporated nucleotide to regenerate a free 3? hydroxyl. The invention has applications in single-cell cDNA library construction and analysis.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: March 8, 2022
    Assignee: DNA Script SAS
    Inventors: Xavier Godron, Adrian Horgan, Sylvain Gariel, Jeffrey Jeddeloh, Robert Nicol, Thomas Ybert
  • Patent number: 11219588
    Abstract: The present disclosure provides a method of inducing or promoting darkening of the skin and/or melanogenesis, a method of treating a skin condition or disorder, in particular hypopigmentation, comprising administration of a polycationic aliphatic amine, wherein said polycationic aliphatic amine preferably is putrescine, spermidine and spermine. The invention further includes corresponding methods of reducing or preventing darkening of skin and/or melanogenesis, or related methods of treating a skin condition or disorder, comprising administration of at least an inhibitor of polycationic aliphatic amine transport or synthesis, wherein said inhibitor is preferably trimer44NMe or difluoromethylornithine (DFMO) respectively.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: January 11, 2022
    Assignee: Agency for Science, Technology and Research
    Inventors: Leah Vardy, Aishwarya Sridharan
  • Patent number: 11219649
    Abstract: The present invention relates to novel compositions comprising specific consortia of living bacteria strains; to the manufacturing of such compositions, particularly by co-cultivation; and to the use of such compositions in pharmaceutical applications, such as the treatment of diseases associated with intestinal microbiota dysbiosis, particularly intestinal infections such as CDI (Clostridium difficile infection) and IBD (Inflammatory bowel diseases). When compared to the traditional FMT therapy () the inventive compositions () are more efficient and safer as demonstrated on an acute colitis model and therefore more appropriate for therapeutic use.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: January 11, 2022
    Assignees: ETH Zurich, UNIVERSITÄT ZÜRICH
    Inventors: Christophe Lacroix, Tomas De Wouters, Gerhard Rogler, Christophe Chassard, Laura Berchtold, Fabienne Kurt, Michael Martin Scharl, Marianne Rebecca Spalinger, Markus Reichlin, Florian Nils Rosenthal, Marco Meola
  • Patent number: 11202800
    Abstract: The present invention relates to the treatment of refractory Emotional Cognitive Disconnect (ECD) through a combination of pharmaceutical agents and therapy. Individual patients are treated with a combination of magnesium, inositol, and N-acetylcysteine along with Vitamin E, Vitamin C, zinc, biotin, alphalipoic acid and lysine as required. The compositions may be administered sequentially or simultaneously in any order and may be formulated in singular or combinatorial dosage forms.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: December 21, 2021
    Inventor: Jeanne Fleming
  • Patent number: 11186845
    Abstract: Compositions for chemical and/or genetic modification of chloroplasts of plants include a functionalized nanoparticle composition linked to a chloroplast-targeting peptide and a functionalized single walled carbon nanotube (SWNT) composition complexed with a nucleic acid cassette encoding a plastid-specific ribosomal RNA operon (prrn). Methods for chemically and/or genetically modifying chloroplasts of plants include administering these chloroplast-targeted compositions to the leaves of live plants.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Juan Pablo Giraldo Gomez, Peiguang Hu, Israel Santana, Gregory Newkirk, Honghong Wu
  • Patent number: 11172693
    Abstract: A feed additive composition comprising a direct fed microbial in combination with a protease, and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject, which method comprising administering to a subject a direct fed microbial in combination with a protease and a phytase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: November 16, 2021
    Assignee: DuPont Nutrition Biosciences APS
    Inventor: Luis Fernando Romero Millan
  • Patent number: 11173135
    Abstract: The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 16, 2021
    Assignee: Thiogenesis Therapeutics, Inc.
    Inventors: Vincent P. Stanton, Jr., Patrice P. Rioux
  • Patent number: 11147872
    Abstract: The present invention refers to new conjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines and formulations containing the same. In addition, the present invention concerns the use of these vaccines in particular for the protection of the human population, and in particular for the protection of the paediatric population from pulmonary and systemic infections due to S. pneumoniae, N. meningitidis, H. influenzae, K. pneumoniae, M. tuberculosis, S. aureus, or from intestinal infections due to S. typhi, V. cholerae and E. coli. The present invention additionally refers to new polyvalent glycoconjugate vaccines for the protection from C. albicans and E. coli systemic and genitourinary infections or for the protection from M. bovis infections in veterinary medicine.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: October 19, 2021
    Assignee: BIOSYNTH S.R.L.
    Inventor: Massimo Porro
  • Patent number: 11149267
    Abstract: The present invention generally relates to libraries, kits, methods, applications and screens used in functional genomics that focus on gene function in a cell and that may use vector systems and other aspects related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and components thereof. The present invention also relates to rules for making potent single guide RNAs (sgRNAs) for use in CRISPR-Cas systems. Provided are genomic libraries and genome wide libraries, kits, methods of knocking out in parallel every gene in the genome, methods of selecting individual cell knock outs that survive under a selective pressure, methods of identifying the genetic basis of one or more medical symptoms exhibited by a patient, and methods for designing a genome-scale sgRNA library.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: October 19, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research
    Inventors: Tim Wang, David Sabatini, Eric Lander
  • Patent number: 11136283
    Abstract: The present invention relates to a process for recovering and purifying resveratrol produced by microbial fermentation. More particularly, the present invention relates to a process for recovering and purifying resveratrol produced by yeast fermentation.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: October 5, 2021
    Assignee: EVOLVA SA
    Inventors: Nicholas Lawrence Ohler, Satish Kumar Bachu, Oliver Frankovic
  • Patent number: 11139064
    Abstract: A system for generating a body degradation reduction program including a computing device configured to receive at least a degradation marker, retrieve a body degradation profile as a function of the at least a degradation marker, assign the body degradation profile to a degradation category, identify, using the degradation category and the body degradation profile, a plurality of nutrition elements, wherein identifying the plurality of nutrient elements includes calculating a plurality of nutrient amounts as a function of a respective effect of each of a plurality of nutrients on the body degradation profile as a function of the degradation category, identifying the plurality of nutrition elements as a function of the plurality of nutrient amounts, and generate a body degradation reduction program, using the plurality of nutrition elements, wherein the body degradation reduction program includes a frequency and a magnitude of consumption of the plurality of nutrition elements.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: October 5, 2021
    Assignee: KPN INNOVATIONS, LLC.
    Inventor: Kenneth Neumann
  • Patent number: 11123444
    Abstract: The present disclosure is directed to methods and a diagnostic kit for producing pericyte information from a subject for identifying and/or treating a subject condition. In one aspect, a method for identifying a subject condition is provided. The method includes administering intravenously to a subject an effective amount of a solution comprising fluorescent markers to selectively label a plurality of pericytes in the subject's body. The method also includes acquiring fluorescence signals originating from labeled pericytes to produce pericyte information associated with tissues of the subject's body. The method further includes generating a report identifying a subject condition using the pericyte information. In some aspects, a treatment may be adapted using the identified subject condition.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: September 21, 2021
    Assignee: Dignity Health
    Inventors: Stephen L. Macknik, Susana Martinez-Conde, Hector Rieiro
  • Patent number: 11116812
    Abstract: Disclosed is a nano-emulsion formulation of saffron and a method of preparation thereof. The method includes the steps of triturating saffron with liquid nitrogen. Preparing an ultrasonic assisted extract in a polar or non-polar solvent. Preparing a nano-emulsion using the extract and one or more surfactants, including tween and span.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: September 14, 2021
    Inventors: Hamed Ahari, AmirAli Anvar, Mehdi Rahimian, Sara Allahyari Beik, Sima Moradi
  • Patent number: 11065294
    Abstract: Provided is a composition for enhancing effects of an anticancer agent using an oriental medicine, jaeumganghwa-tang, bojungikgi-tang, or yukmijihwang-tang. More particularly, provided is a composition for treating a neoplastic disease by administering an anticancer agent into an individual, and administering an oriental medicine into the individual within 30 minutes. The composition remarkably reduces side effects occurring when the anticancer agent is administered alone by co-administration of the oriental medicine, reduces cytotoxicity, and has higher anticancer activity than that when the anticancer agent is administered alone.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: July 20, 2021
    Assignee: COMPREHENSIVE AND INTEGRATIVE MEDICINE INSTITUTE
    Inventors: Joon Seok Byun, Sae Kwang Ku, Ki Cheul Sohn, Seung Mo Kim, Chang Hyeong Lee, Dae Sung Hyun, Jong Dae Kim, Sung Hwan Park, Min A. Kwak
  • Patent number: 11053271
    Abstract: The disclosure provides methods and compositions for the integration (insertion) of a donor DNA molecule into a target DNA molecule. In general, the methods include contacting a target DNA molecule with a linear donor DNA molecule and a Cas 1 protein, where the target DNA molecule includes an AT-rich region (e.g., in some cases positioned 5 and within 50 nucleotides of a region that forms a DNA cruciform structure), where the contacting is not in a bacterial or archaeal cell (e.g., the contacting is in vitro outside of a cell, inside of a eukaryotic cell, etc.), and provides for integration of the donor DNA molecule into the target DNA molecule.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: July 6, 2021
    Assignee: The Regents of the University of California
    Inventors: James K. Nunez, Jennifer A. Doudna
  • Patent number: 11049591
    Abstract: A system and method is disclosed that establishes communication between a host system and a user device. The host system automatically registers individualized diet data received from the user device. The individualized diet data has parameters indicative of type and quantity of foods or supplements consumed by a user during a defined time period. The parameters are analyzed with a predetermined rule set indicative of concentrations of DHA in select foods and supplements to determine a level of the user's DHA dietary intake relative to a recommended intake. An alert is generated by the host system and transmitted via at least one predetermined communication method and without user intervention, responsive to the user's dietary intake relative to the recommended intake being a predetermined relation to a baseline.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: June 29, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Manxi Bai, Jie Huang
  • Patent number: 11041173
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 22, 2021
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Randall Jeffrey Platt, Guoping Feng, Yang Zhou
  • Patent number: 11033575
    Abstract: The present invention relates to the treatment of refractory Emotional Cognitive Disconnect (ECD) through a combination of pharmaceutical agents and therapy. Individual patients are treated with a combination of magnesium, inositol, and N-acetylcysteine along with Vitamin E, Vitamin C, zinc, biotin, alphalipoic acid and lysine as required. The compositions may be administered sequentially or simultaneously in any order and may be formulated in singular or combinatorial dosage forms.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: June 15, 2021
    Inventor: Jeanne Fleming
  • Patent number: 11016104
    Abstract: A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: May 25, 2021
    Assignee: CUREMARK, LLC
    Inventor: Joan M. Fallon
  • Patent number: 11008554
    Abstract: Disclosed herein are methods for the large-scale production of a highly thermally stable acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Additionally, the expression methods disclosed herein can produce ChE preparations consisting of extract or purified forms that can be produced in high amounts and are highly thermally stable. These ChE products can be used in vitro detection, detoxification and decontamination methods.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: May 18, 2021
    Assignee: PlantVax, Inc.
    Inventor: Yvonne J. Rosenberg
  • Patent number: 11001844
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 11, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • Patent number: 10973859
    Abstract: Compositions include arginine and one or more unsaturated fatty acids. Methods for using such compositions can enhance cognitive function, reduce or prevent a decline of social interaction, reduce or prevent age-related behavioral changes, increase trainability, maintain optimal brain function, facilitate learning and memory, reduce memory loss, retard brain aging, prevent or treat strokes, and/or prevent or treat dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: April 13, 2021
    Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S. A.
    Inventor: Yuanlong Pan
  • Patent number: 10946108
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: March 16, 2021
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HAVARD COLLEGE
    Inventors: Feng Zhang, Le Cong, Fei Ran, Matthias Heidenreich, Lukasz Swiech
  • Patent number: 10925934
    Abstract: A spray dried myrosinase/ascorbate mixture is formed from the steps comprising: providing a source of myrosinase, adding ascorbate to the source of myrosinase, heating the source of myrosinase to a temperature of about 104° F. (about 40° C.) or higher, and spray drying the myrosinase/ascorbate mixture. The spray dried myrosinase/ascorbate mixture may be used to prepare isothiocyanates. The spray dried myrosinase/ascorbate mixture may also be mixed with glucoraphanin and used in an activated tablet or capsule.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: February 23, 2021
    Assignee: Caudill Seed and Warehouse Co., Inc.
    Inventors: Richard C. Sullivan, Joseph A. Lyons, Sanford D. Caudill
  • Patent number: 10898525
    Abstract: A preparation comprising krill oil and phospholipids. Methods of treatment comprising administering the same.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: January 26, 2021
    Assignee: AKER BIOMARINE ANTARCTIC AS
    Inventors: Sigalit Zchut, Itay Shafat, Inbal Eyal, Gai Ben-Dror, Hala Laoz, Ofer Bonen
  • Patent number: 10894062
    Abstract: The embodiments relate to improved vitamin supplement compositions formulated for administration to patients, particularly improved vitamin compositions formulated for use in cosmetic or therapeutic applications. The compositions may be used to slow aging process and promote wellness including treating a vitamin deficiency, skin conditions, improving skin appearance, wound healing and scar prevention and hair loss.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: January 19, 2021
    Assignee: AQUAVIT PHARMACEUTICALS, INC.
    Inventor: Sobin Chang
  • Patent number: 10869955
    Abstract: The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
  • Patent number: 10849878
    Abstract: The agent with antistress, anxiolytic and antidepressant activity and a composition based on it. The invention relates to the field of pharmaceutics, particularly to chemical compounds based on lithium salts, namely to substances with antistress, anxiolytic and antidepressant activity and can be used in medicine, veterinary medicine, and the pharmaceutical industry. The invention discovers the possibility of using lithium ascorbate as an agent with antistress, anxiolytic and antidepressant activity. The claimed composition with antistress, anxiolytic and antidepressant activity, including a lithium salt, contains pyridoxine hydrochloride, thiamine mononitrate and lithium ascorbate as a lithium salt. The use of lithium ascorbate as an agent with antistress, anxiolytic and antidepressant action and the composition based on it, enables to expand the assortment of the agents for indicated administration. At the same time, the claimed agents have low toxicity and high efficacy.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: December 1, 2020
    Assignee: OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU “NORMOFARM”
    Inventors: Viacheslav Valerievich Rastashanskiy, Konstantin Sergeevich Ostrenko
  • Patent number: 10822606
    Abstract: Methods, compositions, and kits are provided herein for CRISPER/Cas-mediated nucleic acid detection or modification.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: November 3, 2020
    Assignee: The Regents of the University of California
    Inventors: Bo Huang, Baohui Chen, Lei Qi, Luke Gilbert
  • Patent number: 10813984
    Abstract: The present invention provides a peptide-based immunotherapy for ASPH-expressing tumors.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: October 27, 2020
    Assignee: Rhode Island Hospital
    Inventor: Jack R. Wands
  • Patent number: 10781444
    Abstract: The present invention generally relates to libraries, compositions, methods, applications, kits and screens used in functional genomics that focus on gene function in a cell and that may use vector systems and other aspects related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and components thereof. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: September 22, 2020
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Ophir Shalem, Neville Espi Sanjana, John Doench, David Root, Ella Nicole Biewener Hartenian
  • Patent number: 10765641
    Abstract: The present invention relates to the novel combination of pongamia oil and 4-t-butylcyclohexanol, and to the uses thereof in the fields of cosmetics and dermatology to combat redness. More specifically, the present invention relates to the cosmetic use of a composition comprising said combination to combat rosacea.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: September 8, 2020
    Assignee: PIERRE FABRE DERMOT-COSMETIQUE
    Inventors: Hélène Hernandez-Pigeon, Nathalie Castex-Rizzi, Stéphane Poigny, Marie Françoise Aries, Yves Brunel
  • Patent number: 10717990
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: July 21, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Prashant G. Mali, George M. Church, Luhan Yang
  • Patent number: 10711259
    Abstract: Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity for use in e.g. animal feed. Polypeptides having arabinofuranosidase activity, polypeptides having xylanase activity and polynucleotides encoding the polypeptides. Nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptide.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 14, 2020
    Assignee: Novozymes A/S
    Inventors: Wei Peng, Ninfa Rangel Pedersen, Dan Pettersson, Jens Magnus Ekloff, Soren Nymand-Grarup, Lorena G. Palmen, Rune Nygaard Monrad, Nikolaj Spodsberg, Mary Ann Stringer, Charlotte Blom, Lars Kiemer, Kristian Bertel Romer M. Krogh, Jesper Salomon
  • Patent number: 10704098
    Abstract: Compositions and methods for the treatment and diagnosis of eosinophilic esophagitis disclosed.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 7, 2020
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Patrick Sleiman
  • Patent number: 10695320
    Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: June 30, 2020
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher Rinsch, William Blanco-Bose
  • Patent number: 10655123
    Abstract: The invention provides a method of modifying a targeted site of a double stranded DNA, including a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and a nucleic acid base converting enzyme are linked, with the double stranded DNA, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site, without cleaving at least one strand of the double stranded DNA in the targeted site.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: May 19, 2020
    Assignee: National University Corporation Kobe University
    Inventors: Keiji Nishida, Akihiko Kondo, Satomi Kojima
  • Patent number: 10568843
    Abstract: The present invention provides a method of preparing highly stable microcapsule powders or microparticles containing a fat-soluble nutrient having multiple double bonds.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: February 25, 2020
    Assignee: Zhejiang Medicine Co., Ltd
    Inventors: Xinde Xu, Di Zhou, Lihua Zhang, Bin Shao
  • Patent number: 10568866
    Abstract: A composition of natural and chemical nutrients such as Vitamin C, Vitamin B-complex, Vitamin E, Aronia melanocarpa extract, Fucoidan, Ginger extract, Zinc, Selenium, Alpha lipoic acid, White mulberry extract, Lychee fruit extract and Sour (Tart) cherry fruit extract are made for mammal consumption in liquid or solid form. This specific composition is used for increasing innate immunity in the mammal before and after the infection has occurred.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: February 25, 2020
    Inventor: Matthias W Rath
  • Patent number: 10519324
    Abstract: Materials and methods for prevention of biofouling are described that incorporate the presence of a conotoxin peptide on a surface. The conotoxin peptide is either directly or indirectly adhered to the surface and interferes with the ability of biofouling organisms to settle on the surface.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: December 31, 2019
    Assignee: Clemson University Research Foundation
    Inventors: Andrew S. Mount, Bin San Chan, Mary Beth Johnstone
  • Patent number: 10519504
    Abstract: Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: December 31, 2019
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, John Patrick McCook, Rangaprasad Sarangarajan